Search - tctmd.com

Displaying 61 - 80 of 159

Sort: Relevancy | Date

Presentation TCT 2017

The Inflammatory Hypothesis After CANTOS: CIRT

Presenter: Bernard J. Gersh, Robert A. Harrington, Wolfgang Koenig

October 30, 2017

Presentation TCT 2017

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Presenter: Bernard J. Gersh, Robert A. Harrington, Wolfgang Koenig

October 30, 2017

Presentation TCT 2017

Should Alleviating ISCHEMIA Be the Goal?

Presenter: Bernard J. Gersh, Robert A. Harrington, David J. Moliterno

October 30, 2017

Presentation TCT 2017

Primary Prevention in High Risk Patients II: THEMIS

Presenter: Bernard J. Gersh, Robert A. Harrington

October 30, 2017

Presentation TCT 2017

Primary Prevention In High Risk Patients I: REPRIEVE

Presenter: Bernard J. Gersh, Robert A. Harrington, Pamela S. Douglas

October 30, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Opinion Editor's Corner TCT 2016

我对 2016 年 TCT 的总结：惊喜、假设和赠品

Shelley Wood

November 07, 2016

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Shelley Wood

November 07, 2016

News Opinion Editor's Corner TCT 2016

Con Qué Me Quedo de TCT 2016: Sorpresas, Presuposiciones y Revelaciones

Shelley Wood

November 07, 2016

Presentation TCT 2016

Pragmatic Simple Trials and Big Data: Advantages and Caveats

Presenter: Deepak L. Bhatt, Roxana Mehran, Robert A. Harrington

October 31, 2016

Presentation TCT 2016

When Are Randomized Trials Not Enough, and Can Observational Data Reliably Inform Comparative Effectiveness Decisions?

Presenter: Eugene H. Blackstone, Robert W. Yeh, Robert A. Harrington

October 30, 2016

Presentation TCT 2016

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

Presenter: Roxana Mehran, Pascal Vranckx, Robert A. Harrington

October 30, 2016

Presentation TCT 2016

Personalized Medicine Where Are We in 2016?

Presenter: Robert A. Harrington, A. Michael Lincoff, Clyde W. Yancy

October 30, 2016

Presentation TCT 2016

Anti-inflammatory Therapies for Atherosclerosis

Presenter: Robert A. Harrington, A. Michael Lincoff, Jean-Claude Tardif

October 30, 2016

Presentation TCT 2016

Heart Failure Advances (Ivabradine, ARNI, and More)

Presenter: Robert A. Harrington, A. Michael Lincoff, Clyde W. Yancy

October 30, 2016

Presentation TCT 2016

Diabetes Advances (SGLT-2, GLP-1, DPP4)

Presenter: Robert A. Harrington, A. Michael Lincoff, Norman E. Lepor

October 30, 2016

News Daily News

Twitter Review Reveals Clues as to Who, When, and What Users Are Tweeting About Cardiovascular Disease Online

Yael L. Maxwell

September 28, 2016

News Conference News ESC 2016

N-Acetylcysteine for Myocardial Salvage in STEMI? NACIAM Trial Treads Where Many Have Flopped Before

Shelley Wood

August 28, 2016

News Daily News

Galen Strohm Wagner, Who Helped Establish the Duke Databank for Cardiovascular Disease, Dies Age 76

Michael H. Wilson

July 14, 2016

Advertisement

The Inflammatory Hypothesis After CANTOS: CIRT

The LDL Hypothesis Post FOURIER: Heading Home From ODYSSEY

Should Alleviating ISCHEMIA Be the Goal?

Primary Prevention in High Risk Patients II: THEMIS

Primary Prevention In High Risk Patients I: REPRIEVE

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

我对 2016 年 TCT 的总结：惊喜、假设和赠品

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Con Qué Me Quedo de TCT 2016: Sorpresas, Presuposiciones y Revelaciones

Pragmatic Simple Trials and Big Data: Advantages and Caveats

When Are Randomized Trials Not Enough, and Can Observational Data Reliably Inform Comparative Effectiveness Decisions?

Choice of Primary (or Co-primary) Endpoints: Efficacy, Safety, or Net Clinical Benefit in Superiority and Non-inferiority Trials

Personalized Medicine Where Are We in 2016?

Anti-inflammatory Therapies for Atherosclerosis

Heart Failure Advances (Ivabradine, ARNI, and More)

Diabetes Advances (SGLT-2, GLP-1, DPP4)

Twitter Review Reveals Clues as to Who, When, and What Users Are Tweeting About Cardiovascular Disease Online

N-Acetylcysteine for Myocardial Salvage in STEMI? NACIAM Trial Treads Where Many Have Flopped Before

Galen Strohm Wagner, Who Helped Establish the Duke Databank for Cardiovascular Disease, Dies Age 76

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content